本文關(guān)鍵詞：丙型肝炎病毒結(jié)構(gòu)基因的表達(dá)及其病毒樣顆粒研究　出處：《第二軍醫(yī)大學(xué)》2005年博士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 丙型肝炎病毒 病毒樣顆粒 核心基因 E2基因桿狀病毒 昆蟲(chóng)細(xì)胞 融合表達(dá) 免疫 抗原性 免疫原性 疫苗

【摘要】：丙型肝炎病毒(Hepatitis Cvirus,HCV)是引起人類急、慢性肝炎的主要致病因子之一,全球HCV感染者約1.7億人,約50～80%感染者發(fā)展成慢性,其中約10～20%發(fā)展為肝硬化,約1%～5%可發(fā)展為肝癌。由于迄今仍缺乏合適的HCV體外增殖系統(tǒng)及適宜的小動(dòng)物模型,嚴(yán)重制約了HCV疫苗的研制。HCV為單正鏈RNA病毒,基因組RNA長(zhǎng)約9.5kb,僅有一個(gè)開(kāi)放讀碼框架(ORF),編碼一約3011個(gè)氨基酸的多聚蛋白前體,該前體蛋白在宿主信號(hào)肽酶及病毒蛋白酶作用下,裂解為病毒的結(jié)構(gòu)蛋白與非結(jié)構(gòu)蛋白。三個(gè)結(jié)構(gòu)蛋白包括核心蛋白、包膜蛋白E1和E2在誘導(dǎo)機(jī)體體液和細(xì)胞免疫應(yīng)答中起著關(guān)鍵性作用,成為研究HCV疫苗的靶抗原。因此,本研究選擇Bac-to-Bac桿狀病毒表達(dá)系統(tǒng),首先表達(dá)截短的HCV核心蛋白和EGFP融合蛋白,探討重組桿狀病毒表達(dá)載體的轉(zhuǎn)染效率和表達(dá)效果。再表達(dá)全長(zhǎng)的HCV核心蛋白和截短的E2融合蛋白,分別研究其抗原性。在此基礎(chǔ)上,我們同時(shí)構(gòu)建含HCV全部結(jié)構(gòu)基因的三種重組桿狀病毒表達(dá)載體,獲得重組各種重組桿狀病毒,探討HCV全長(zhǎng)結(jié)構(gòu)基因(C-E1-E2)在昆蟲(chóng)細(xì)胞中的表達(dá)及其裝配形成VLP的特點(diǎn),研究VLP在體外和各種細(xì)胞的結(jié)合特征、抗原性以及在動(dòng)物體內(nèi)的免疫原性。 一、丙型肝炎病毒核心抗原和綠色熒光蛋白基因的融合表達(dá) 用PCR方法從含HCV全長(zhǎng)cDNA的質(zhì)粒pGEM-HCJ4中擴(kuò)增出截短的核心蛋白基因片段(Ct),將其插入轉(zhuǎn)座子載體pFastBacl,得到重組轉(zhuǎn)座質(zhì)粒pFastCt。用PCR方法從含有增強(qiáng)綠色熒光蛋白基因的表達(dá)質(zhì)粒pEGFP-N1上擴(kuò)增出EGFP基因,再將其亞克隆到pFastCt中HCV核心基因之后,構(gòu)建成融合表達(dá)載體pFastCt-EGFP。鑒定后將其轉(zhuǎn)化大腸桿菌DH10Bac,經(jīng)細(xì)菌內(nèi)的轉(zhuǎn)座作用,得到穿梭質(zhì)粒BacmidCt-EGFP。以之轉(zhuǎn)染昆蟲(chóng)Sf9細(xì)胞,通過(guò)熒光顯微鏡觀察EGFP來(lái)計(jì)數(shù)轉(zhuǎn)染陽(yáng)性細(xì)胞的數(shù)量,發(fā)現(xiàn)高分子量質(zhì)粒BacmidCt-EGFP的轉(zhuǎn)染效率遠(yuǎn)遠(yuǎn)不及小分子量質(zhì)粒pEGFP-N1,通過(guò)系列實(shí)驗(yàn)比對(duì)使用不同濃度高分子量質(zhì)粒進(jìn)行轉(zhuǎn)染所取得的效果,為后續(xù)的轉(zhuǎn)染實(shí)驗(yàn)確定了Bacmid用量的基數(shù)。從BacmidCt-EGFP轉(zhuǎn)染的細(xì)胞培養(yǎng)上清中獲得了重組桿狀病毒rBacCt-EGFP,經(jīng)過(guò)SDS-PAGE和western blot鑒定,發(fā)現(xiàn)其成功表達(dá)了分子量約40000融合蛋白。以ELISA方法檢測(cè)發(fā)現(xiàn)該融合蛋白能與28份HCV陽(yáng)性血清中的15份發(fā)生反應(yīng),陽(yáng)性率為54%,表明其具有一定的抗原性。 二、HCV核心和截短的包膜蛋白E2基因在昆蟲(chóng)細(xì)胞中的表達(dá)及其抗原性 以pGEM-HCJ4質(zhì)粒為模板,分別用PCR擴(kuò)增出完整C基因和截短的E2基因片段,再分別與pMD18-T載體連接,得到重組質(zhì)粒pMD-C和pMD-E2t。用BamHI和XbaI酶切pMD-C,用XbaI和EcoRI酶切pMD-E2t,分別回收酶切的C基因和
[Abstract]:Hepatitis C virus (HCV) is one of the main causes of acute and chronic hepatitis in humans. There are about 170 million people infected with HCV in the world. About 50% of the infected patients developed chronic, of which about 10% developed cirrhosis. About 1 / 5% of HCV vaccine can be developed into hepatoma. Because of the lack of suitable HCV proliferation system in vitro and a suitable small animal model, the development of HCV vaccine. HCV is a single positive strand RNA virus. The genomic RNA is about 9.5 kb long and has only one open reading frame, ORF, which encodes a polymeric protein precursor of about 3011 amino acids. Under the action of host signal peptidase and viral protease, the precursor protein is divided into structural protein and non-structural protein of virus. The three structural proteins include core protein. Envelope proteins E1 and E2 play a key role in inducing humoral and cellular immune responses and become the target antigens for the study of HCV vaccines. In this study, Bac-to-Bac baculovirus expression system was selected to express truncated HCV core protein and EGFP fusion protein. To investigate the transfection efficiency and expression effect of recombinant baculovirus expression vector, and then express the full-length HCV core protein and truncated E2 fusion protein, and study the antigenicity of the recombinant baculovirus expression vector. At the same time, we constructed three recombinant baculovirus expression vectors containing all the structural genes of HCV, and obtained recombinant baculovirus. To investigate the expression of HCV full-length gene C-E _ 1-E _ 2 in insect cells and the characteristics of its assembly to form VLP, and to study the binding characteristics of VLP with various cells in vitro. Antigenicity and immunogenicity in animals. Fusion expression of hepatitis C virus core antigen and green fluorescent protein gene The truncated core protein gene fragment was amplified by PCR from the plasmid pGEM-HCJ4 containing the full-length cDNA of HCV. It was inserted into transposon carrier pFastBacl. The recombinant transposable plasmid pFastCt.The EGFP gene was amplified by PCR from the expression plasmid pEGFP-N1 containing enhanced green fluorescent protein gene. The fusion vector pFastCt-EGFP. was constructed after subcloned into the HCV core gene of pFastCt. The recombinant plasmid was identified and transformed into Escherichia coli DH10Bac. The shuttle plasmid BacmidCt-EGFP. was transfected into insect Sf9 cells by transposition in bacteria. EGFP was observed by fluorescence microscope to count the number of transfected positive cells. It was found that the transfection efficiency of high molecular weight plasmid BacmidCt-EGFP was much lower than that of small molecular weight plasmid pEGFP-N1. A series of experiments were carried out to compare the effect of transfection with different concentrations of high molecular weight plasmids. The base number of Bacmid was determined for the subsequent transfection experiment. Recombinant baculovirus rBacCt-EGFP was obtained from the supernatant of cell culture transfected with BacmidCt-EGFP. It was identified by SDS-PAGE and western blot. It was found that the fusion protein with molecular weight of about 40000 was successfully expressed. The fusion protein could react with 15 out of 28 HCV positive sera by ELISA method, and the positive rate was 54%. It shows that it has certain antigenicity. Expression and antigenicity of HCV core and truncated envelope protein E2 gene in insect cells Using pGEM-HCJ4 plasmid as template, complete C gene and truncated E2 gene fragments were amplified by PCR, and then ligated with pMD18-T vector respectively. The recombinant plasmids pMD-C and pMD-E2twere digested with BamHI and XbaI, and the pMD-E2t was digested with XbaI and EcoRI. The C gene and the digested C gene were recovered respectively.
【學(xué)位授予單位】：第二軍醫(yī)大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2005
【分類號(hào)】：R373

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 凌應(yīng)俠，徐恒士;皖北地區(qū)三個(gè)特定獻(xiàn)血人群的丙型肝炎調(diào)查[J];蚌埠醫(yī)學(xué)院學(xué)報(bào);1996年04期

2 張普柱，郭志均，汪洋，張明良;燒傷病人輸血后丙肝發(fā)生情況報(bào)告[J];北京醫(yī)學(xué);1995年06期

3 洪萍;朱培元;;微陣列技術(shù)在輸血醫(yī)學(xué)中的應(yīng)用及其研究進(jìn)展[J];中國(guó)輸血雜志;2006年05期

4 唐榮智;錢水娟;王珍;;輸血后丙肝法律責(zé)任探析[J];北京政法職業(yè)學(xué)院學(xué)報(bào);2006年02期

5 姚愛(ài)卿，趙中夫，郭懷文,趙亞模，賈替云;丙型肝炎病毒醫(yī)源性感染的初步探討[J];長(zhǎng)治醫(yī)學(xué)院學(xué)報(bào);1994年02期

6 戚中田,潘衛(wèi),杜平;中國(guó)人丙型肝炎病毒核心基因cDNA的克隆與序列分析[J];第二軍醫(yī)大學(xué)學(xué)報(bào);1992年04期

7 戚中田;庚型肝炎病毒研究現(xiàn)狀與展望[J];第二軍醫(yī)大學(xué)學(xué)報(bào);2000年09期

8 劉佩芝,程江,張愛(ài)萍;七年間輸血后肝炎調(diào)查分析[J];實(shí)用肝臟病雜志;2000年02期

9 許明星;胡業(yè)敬;;毒癮者丙型肝炎和乙型肝炎重疊感染危險(xiǎn)因素的研究[J];華南預(yù)防醫(yī)學(xué);2006年04期

10 朱月娥，，曾德榮，源柏定，曾蓮香;海珠區(qū)正常人群HBV標(biāo)志物與HCV雙重感染的調(diào)查[J];廣東衛(wèi)生防疫;1994年02期

相關(guān)博士學(xué)位論文 前3條

1 高軍;丙型肝炎病毒多表位抗原的基因合成與免疫原性研究[D];第二軍醫(yī)大學(xué);2004年

2 晉云;肝細(xì)胞癌SuperArray腫瘤轉(zhuǎn)移相關(guān)基因芯片篩選及Cathepsin L表達(dá)實(shí)驗(yàn)研究[D];第三軍醫(yī)大學(xué);2008年

3 李澤松;缺失型α-地中海貧血基因診斷芯片及在分子流行病學(xué)研究中的應(yīng)用[D];重慶大學(xué);2008年

相關(guān)碩士學(xué)位論文 前4條

1 許江城;屠宰豬肝臟人病毒性肝炎的病原學(xué)初探和病理學(xué)研究[D];中國(guó)農(nóng)業(yè)大學(xué);2004年

2 張壽國(guó);丙型肝炎NS5A基因的克隆、表達(dá)和抗原性分析[D];安徽醫(yī)科大學(xué);2003年

3 余章斌;蛋白質(zhì)微陣列技術(shù)在檢測(cè)TORCH感染中的實(shí)驗(yàn)研究[D];東南大學(xué);2006年

4 鄭琳琳;探針編碼實(shí)時(shí)PCR的基因分型研究[D];廈門大學(xué);2006年

本文編號(hào)：1389361